Adults with type 2 diabetes who initiate SGLT2 inhibitors within 3 months of a diagnosis of a urinary tract infection have a ...

Canagliflozin is generally well tolerated and improves blood sugar control in children and adolescents with type 2 diabetes, ...

No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) ...

Germany: A retrospective cohort study has found that prior use of SGLT2 inhibitors in type 2 diabetes mellitus (T2DM) ...

Children and adolescents with type 2 diabetes had greater reductions in HbA1c with an oral SGLT2 inhibitor compared with ...

Sodium glucose cotransporter 2 (SGLT2) inhibitors provide better glycemic control in patients with type 2 diabetes and reduce the risks for cardiovascular events, kidney disease progression, and ...

Adults with diabetes who use SGLT2 inhibitors have lower risks for developing most types of cancer compared with nonusers, though the risk for pancreatic cancer is higher among SGLT2 users ...

Of note, the researchers projected that first-line SGLT2 inhibitors and GLP-1 receptor agonists would slightly increase overall life expectancy, by 3 and 3.4 months, respectively.

With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious. AstraZeneca had already been quick to consider ...

There’s no question that SGLT2 inhibitors are coming to make a difference. Neil Minkoff, MD: Let me ask Dr Desai, and I’ll come right back to you, Steve.

HFrEF: Use SGLT2 inhibitors to reduce your risk of a hospital admission for heart failure and to reduce your risk of dying from heart problems, even if you do not have type 2 diabetes.

As expected from the trials, the SGLT2 inhibitor initiators had a higher risk for genital infections (HR 2.19, 95% CI 1.91-2.51), but otherwise similar safety compared with metformin initiators.